Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,866 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neoplasm, Prostate Clear all
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

NCT04703920
View directory record Official record
Conditions
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma, Metastic or Unresectable Pancreatic Adenocarcinoma
Interventions
Talazoparib, Belinostat
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 1 Interventional

Robotic Seed Implantation for Prostate Cancer Brachytherapy

NCT01341288
View directory record Official record
Conditions
Prostate Cancer
Interventions
EUCLIDIAN Robot
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
40 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 2Phase 3 Interventional

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670
View directory record Official record
Conditions
Prostate Cancer
Interventions
Investigators choice of SoC, AAA817
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • Santa Barbara, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Withdrawn No phase listed Observational

Identification of Risk Allels for Prostate Cancer

NCT00323388
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jul 22, 2026, 10:41 AM EDT
Not listed Phase 1 Interventional

TNFerade Biologic to Treat Locally Advanced Prostate Cancer

NCT01048151
View directory record Official record
Conditions
Locally Advanced Prostate Cancer
Interventions
TNFerade™ Biologic
Biological
Lead sponsor
GenVec
Industry
Eligibility
Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2012 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

NCT00425503
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
PS-341 (bortezomib)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

NCT00331773
View directory record Official record
Conditions
Prostate Cancer
Interventions
Conventional 3D-CRT or IMRT, Hypofractionated 3D-CRT or IMRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
282
States / cities
Phoenix, Arizona • Tucson, Arizona • Auburn, California + 200 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jul 22, 2026, 10:41 AM EDT
Not yet recruiting Phase 2 Interventional

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

NCT07574541
View directory record Official record
Conditions
Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type
Interventions
TriAdeno vaccine, N-803
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated No phase listed Observational

Laparoscopic Vs. Open Prostatectomy Outcomes

NCT00695773
View directory record Official record
Conditions
Prostate Cancer Surgery
Interventions
Not listed
Lead sponsor
Lahey Clinic
Other
Eligibility
Male only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2008 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

NCT00474383
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
Abiraterone acetate, Glucocorticoid
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Redes III Patient Navigator Qol Study

NCT02275754
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions
PN+LCNC, PN Only
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

NCT01505868
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
Interventions
Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

NCT01415960
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
San Diego, California • Daytona Beach, Florida • Ocala, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

NCT05551117
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
Interventions
vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

NCT02555189
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
Interventions
Enzalutamide, Ribociclib, Laboratory Biomarker Analysis, Pharmacological Study, Biospecimen Collection, Biopsy, Echocardiography, Multigated Acquisition Scan, Bone Scan, Computed Tomography, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Ann Arbor, Michigan • Buffalo, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Cultured Circulating Tumor Cells in Prostate and Other Cancers

NCT02123862
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Oscar Goodman, Jr.
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

NCT01533246
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
linsitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986
View directory record Official record
Conditions
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Interventions
AMO959, AAA617, Enzalutamide, Abiraterone
Drug · Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Los Angeles, California • El Paso, Texas • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Not listed Early Phase 1 Interventional

Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint

NCT01394042
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proxiscan device
Device
Lead sponsor
Radiological Associates of Sacramento Medical Group Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Roseville, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Jul 22, 2026, 10:41 AM EDT
Completed No phase listed Observational

Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis

NCT00264017
View directory record Official record
Conditions
Prostate Cancer Patients Undergoing External Radiation and Seed Implantation
Interventions
Not listed
Lead sponsor
Dattoli Cancer Center and Brachytherapy Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
60 participants
Timeline
2005
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2005 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Not applicable Interventional

InBody Band 3 Fitness Tracker to Improve Health Outcomes and Quality of Life in Black Prostate Cancer Survivors

NCT06703996
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Discussion, Medical Device Usage and Evaluation, Questionnaire Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

NCT01377389
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab, Leuprolide, Goserelin, Degarelix
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00488982
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Docetaxel and GM-CSF
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jul 22, 2026, 10:41 AM EDT